Incidence and prevalence of heart failure in England: a descriptive analysis of linked primary and secondary care data – the PULSE study

por Bellanca, Leana, Linden, Stephan, Farmer, Ruth
Publicado 2023

Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England

por Kolovos, Spyros, Bellanca, Leana, Groyer, Harinala, Rosano, Giuseppe, Gaultney, Jennifer, Linden, Stephan
Publicado 2023

A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction

por Tafazzoli, Ali, Reifsnider, Odette S., Bellanca, Leana, Ishak, Jack, Carrasco, Marc, Rakonczai, Pal, Stargardter, Matthew, Linden, Stephan
Publicado 2022

Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%

por Kolovos, Spyros, Bellanca, Leana, Groyer, Harinala, Rosano, Giuseppe M.C., Solé, Alexandra, Gaultney, Jennifer, Linden, Stephan
Publicado 2023

Aerobic exercise for vasomotor menopausal symptoms: A cost-utility analysis based on the Active Women trial

por Goranitis, Ilias, Bellanca, Leana, Daley, Amanda J., Thomas, Adele, Stokes-Lampard, Helen, Roalfe, Andrea K., Jowett, Sue
Publicado 2017